● Recruiting

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Condition: Acute Myeloid Leukemia · Myelodysplastic Syndrome · Blastic Plasmacytoid Dendritic Cell Neoplasm · Sponsor: Dana-Farber Cancer Institute

PhasePhase 1

Planned participants72

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: * SL-401 * Azacitidine * Venetoclax

This description comes directly from the study's public registry record.

Talk to the study team

Andrew Lane, MD, PhD · 857-215-1405 · andrew_lane@dfci.harvard.edu

Veronica Zehnder · veronica_zehnder@dfci.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (3)

City of Hope	Duarte, California, United States	Recruiting
Dana Farber Cancer Institute	Boston, Massachusetts, United States	Recruiting
MD Anderson Cancer Center	Houston, Texas, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03113643